Moderna (NASDAQ:MRNA – Get Free Report) and BioCardia (NASDAQ:BCDA – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.
Analyst Ratings
This is a summary of current ratings and price targets for Moderna and BioCardia, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Moderna | 4 | 15 | 3 | 1 | 2.04 |
| BioCardia | 0 | 0 | 1 | 1 | 3.50 |
Moderna presently has a consensus target price of $60.63, indicating a potential upside of 63.56%. BioCardia has a consensus target price of $25.00, indicating a potential upside of 831.10%. Given BioCardia’s stronger consensus rating and higher possible upside, analysts plainly believe BioCardia is more favorable than Moderna.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Moderna | $3.20 billion | 4.47 | -$3.56 billion | ($9.28) | -3.99 |
| BioCardia | $71,000.00 | 173.35 | -$11.57 million | ($4.19) | -0.64 |
BioCardia has lower revenue, but higher earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Moderna and BioCardia’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Moderna | -110.04% | -28.74% | -21.83% |
| BioCardia | -1,999.77% | N/A | -208.38% |
Institutional and Insider Ownership
75.3% of Moderna shares are owned by institutional investors. Comparatively, 20.6% of BioCardia shares are owned by institutional investors. 15.7% of Moderna shares are owned by insiders. Comparatively, 20.0% of BioCardia shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Risk and Volatility
Moderna has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. Comparatively, BioCardia has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500.
Summary
BioCardia beats Moderna on 8 of the 14 factors compared between the two stocks.
About Moderna
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
About BioCardia
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
-PEIPEI.png?v=2024-07-14&h=45&w=95&zc=2){kind=small}
